(Reuters) – Generic competitors to British drugmaker Indivior Plc’s blockbuster opioid addiction treatment are on course to launch sales next week after the firm’s attempt to stay a U.S. District court judgement was rejected.
The company said on Tuesday it would file a repeat motion to the Supreme Court, after having said last week that it faces rapid losses in market share “in the immediate future” to generic versions of Suboxone.
Earlier this month, a mandate by the U.S. Court of Appeals for the Federal Circuit opened the gates to rivals including India’s Dr. Reddy’s.
Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur
more recommended stories
China reports new bird flu outbreak in Yunnan province
BEIJING (Reuters) – China reported a.
Pharmacist follow-up calls could help curb repeat hospitalizations
(Reuters Health) – Patients sent home.
Venezuela crisis could spark surge in infectious diseases: study
FILE PHOTO: A Venezuelan health worker.
U.S., Canada, Mexico work to prevent swine fever reaching region
ARLINGTON, Va. (Reuters) – The United.
U.S. FDA proposes new regulations for over-the-counter sunscreens
(Reuters) – The U.S. Food and.
Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke
(Reuters) – Catalyst Pharmaceuticals Inc, rebuked.
Catalyst defends $375,000 drug price after Bernie Sanders rebuke
FILE PHOTO: U.S. Senator Bernie Sanders.
Expired drugs may remain effective, safe to use in a pinch
(Reuters Health) – Even medicines that.
China reports new African swine fever outbreak in Yunnan province
BEIJING (Reuters) – China has confirmed.
Johnson & Johnson receives federal subpoenas related to baby powder litigation
(Reuters) – Johnson & Johnson said.
Prescription opioids may play role in some fatal two-car crashes
(Reuters Health) – In fatal two-car.
Younger siblings with older brothers more likely to be bullied
(Reuters Health) – That younger siblings.